The effects of 1 month antihypertensive treatment with perindopril, bisoprolol or both on the ex vivo ability of monocytes to secrete inflammatory cytokines

International Journal of Clinical Pharmacology and Therapeutics

Volumn 47, Issue 11, 2009, Pages 686-694

  Madej, A ^a   Buldak, L ^a   Basiak, M ^a   Szkrobka, W ^a   Dulawa, A ^a   Okopien, B ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Bisoprolol; Cytokines; Hypertension; Monocyte; Perindopril

Indexed keywords

BISOPROLOL; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PERINDOPRIL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; BRADYCARDIA; CONTROLLED STUDY; COUGHING; DRUG EFFICACY; FATIGUE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOCYTE; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN SECRETION;

EID: 70449345836     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP47686     Document Type: Article

References (39)

1. Amann B, Tinzmann R, Angelkort B. ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1. Diabetes Care. 2003; 26: 2421-2425.
2. Bautista LE, Vera LM, Arenas IA, Gamarra G. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-α) and essential hypertension. J Hum Hypertens. 2005; 19: 149-154.
3. Bermudez EA, Rifai N, Buring J, Manson JE, Ridker PM. Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women. Arterioscler. Thromb. Vasc. Biol. 2002; 22: 1668-1673.
4. Biasucci LM, Liuzzo G, Grillo RL, Caligiuri G, Rebuzzi AG, Buffon A, Summaria F, Ginnetti F, Fadda G, Maseri A. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation. 1999; 99: 855-860.
5. Chae CU, Lee RT, Rifai N, Ridker PM. Blood pressure and inflammation in apparently healthy men. Hypertension. 2001; 38: 399-403.
6. De Groote D, Zangerle PF, Gevaert Y, Fassotte MF, Beguin Y, Noizat-Pirenne F, Pirenne J, Gathy R, Lopez M, Dehart I. Direct stimulation of cytokines (IL-1β, TNF-α, IL-6, IL-2, IFN-γ and GM-CSF) in whole blood. I. Comparison with isolated PBMC stimulation. Cytokine. 1992; 4: 239-248.
7. De Martin R, Hoeth M, Hofer-Warbinek R, Schmid JA. The transcription factor NF-κB and the regulation of vascular cell function. Arterioscler. Thromb. Vasc. Biol. 2000; 20: E83-E88.
8. Deo R, Khera A, McGuire DK, Murphy SA, Meo Neto Jde P, Morrow DA, de Lemos JA. Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and subclinical atherosclerosis. J. Am. Coll. Cardiol. 2004; 44: 1812-1818.
9. Dörffel Y, Lätsch C, Stuhlmüller B, Schreiber S, Scholze S, Burmester GR, Scholze J. Preactivated peripheral blood monocytes in patients with essential hypertension. Hypertension. 1999; 34: 113-117.
10. Dörffel Y, Franz S, Pruss A, Neumann G, Rohde W, Burmester GR, Scholze J. Preactivated monocytes from hypertensive patients as a factor for atherosclerosis? Atherosclerosis. 2001; 157: 151-160.
11. Flø RW, Naess A, Lund-Johansen F, Maehle BO, Sjursen H, Lehmann V, Solberg CO. Negative selection of human monocytes using magnetic particles covered by antilymphocyte antibodies. J. Immunol. Methods. 1991; 137: 89-94.
12. Ford ES, Giles WH. Serum C-reactive protein and self-reported stroke: findings from the Third National Health and Nutrition Examination Survey. Arterioscler. Thromb. Vasc. Biol. 2000; 20: 1052-1056.
13. Gage JR, Fonarow G, Hamilton M, Widawski M, Martínez-Maza O, Vredevoe DL. βBlocker and angiotensin-converting enzyme inhibitor therapy is associated with decreased Th1/Th2 cytokine ratios and inflammatory cytokine production in patients with chronic heart failure. Neuroimmunomodulation. 2004; 11: 173-180.
14. Gornikiewicz A, Sautner T, Brostjan C, Schmierer B, Függer R, Roth E, Mühlbacher F, Bergmann M. Catecholamines upregulate lipopolysaccharide-induced IL-6 production in human microvascular endothelial cells. FASEB J. 2000; 14: 1093-1100.
15. Gullestad L, Ueland T, Brunsvig A, Kjekshus J, Simonsen S, Frøland SS, Aukrust P. Effect of metoprolol on cytokine levels in chronic heart failure - a substudy in the Metoprolol Controlled-Release Randomised Intervention Trial in Heart Failure (MERIT-HF). Am. Heart J. 2001; 141: 418-421.
16. Han Y, Runge MS, Brasier AR. Angiotensin II induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-κB transcription factors. Circ. Res. 1999; 84: 695-703.
17. Hernández-Presa M, Bustos C, Ortego M, Tuñon J, Renedo G, Ruiz-Ortega M, Egido J. Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-κB activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation. 1997; 95: 1532-1541.
18. Huang Y, Mironova M, Lopes-Virella MF. Oxidized LDL stimulates matrix metalloproteinase-1 expression in human vascular endothelial cells. Arterioscler Thromb Vasc Biol. 1999; 19: 2640-2647.
19. Lacraz S, Nicod LP, Chicheportiche R, Welgus HG, Dayer JM. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J Clin Invest. 1995; 96: 2304-2310.
20. Lang R, Patel D, Morris JJ, Rutschman RL, Murray PJ. Shaping gene expression in activated and resting primary macrophages by IL-10. J. Immunol. 2002; 169: 2253-2263.
21. Madej A, Okopien B, Kowalski J, Haberka M, Herman ZS Plasma concentrations of adhesion molecules and chemokines in patients with essential hypertension. Pharmacol. Rep. 2005; 57: 878-881.
22. Maus U, Herold S, Muth H, Maus R, Ermert L, Ermert M, Weissmann N, Rosseau S, Seeger W, Grimminger F, Lohmeyer J. Monocytes recruited into the alveolar air space of mice show a monocytic phenotype but upregulate CD14. Am. J. Physiol. Lung Cell Mol. Physiol. 2001; 280: L58-L68.
23. Mizuochi Y, Okajima K, Harada N, Molor-Erdene P, Uchiba M, Komura H, Tsuda T, Katsuya H. Carvedilol, a nonselective β-blocker, suppresses the production of tumor necrosis factor and tissue factor by inhibiting early growth response factor-1 expression in human monocytes in vitro. Transl. Res. 2007; 149: 223-230.
24. Monaco C, Andreakos E, Kiriakidis S, Mauri C, Bicknell C, Foxwell B, Cheshire N, Paleolog E, Feldmann M. Canonical pathway of nuclear factor κB activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis. Proc. Natl. Acad. Sci. USA. 2004; 101: 5634-5639.
25. Nikfardjam M, Müllner M, Schreiber W, Oschatz E, Exner M, Domanovits H, Laggner AN, Huber K. The association between C-reactive protein on admission and mortality in patients with acute myocardial infarction. J. Intern Med. 2000; 247: 341-345.
26. Ohtsuka T, Hamada M, Hiasa G, Sasaki O, Suzuki M, Hara Y, Shigematsu Y, Hiwada K. Effect of β-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy. J. Am. Coll. Cardiol. 2001; 37: 412-417.
27. Okopien B, Krysiak R, Haberka M, Herman ZS. Effect of monthly atorvastatin and fenofibrate treatment on monocyte chemoattractant protein-1 release in patients with primary mixed dyslipidemia. J. Cardiovasc. Pharmacol. 2005; 45: 314-320.
28. Osterud B, Bjorklid E. Role of monocytes in atherogenesis. Physiol. Rev. 2003; 83: 1069-1112.
29. Pauschinger M, Rutschow S, Chandrasekharan K, Westermann D, Weitz A, Peter Schwimmbeck L, Zeichhardt H, Poller W, Noutsias M, Li J, Schultheiss HP, Tschope C. Carvedilol improves left ventricular function in murine coxsackievirus-induced acute myocarditis association with reduced myocardial interleukin-1β and MMP-8 expression and a modulated immune response. Eur. J. Heart Fail. 2005; 7: 444-452.
30. Rahman ST, Lauten WB, Khan QA, Navalkar S, Parthasarathy S, Khan BV. Effects of eprosartan versus hydrochlorothiazide on markers of vascular oxidation and inflammation and blood pressure (renin-angiotensin system antagonists, oxidation, and inflammation). Am. J. Cardiol. 2002; 89: 686-690.
31. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000; 101: 1767-1772.
32. Schillaci G, Pirro M, Gemelli F, Pasqualini L, Vaudo G, Marchesi S, Siepi D, Bagaglia F, Mannarino E. Increased C-reactive protein concentrations in never-treated hypertension: the role of systolic and pulse pressures. J Hypertens. 2003; 21: 1841-1846.
33. Schottelius AJ, Mayo MW, Sartor RB, Baldwin AS Jr. Interleukin-10 signaling blocks inhibitor of κB kinase activity and nuclear factor kappaB DNA binding. J. Biol. Chem. 1999; 274: 31868-31874.
34. Sesso HD, Wang L, Buring JE, Ridker PM, Gaziano JM. Comparison of interleukin-6 and C-reactive protein for the risk of developing hypertension in women. Hypertension. 2007; 49: 304-310.
35. Stumpf C, John S, Jukic J, Yilmaz A, Raaz D, Schmieder RE, Daniel WG, Garlichs CD. Enhanced levels of platelet P-selectin and circulating cytokines in young patients with mild arterial hypertension. J. Hypertens. 2005; 23: 995-1000.
36. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol. Rev. 2006; 86: 515-581.
37. von der Thüsen JH, Kuiper J, van Berkel TJ, Biessen EA. Interleukins in atherosclerosis: molecular pathways and therapeutic potential. Pharmacol. Rev. 2003; 55: 133-166.
38. Xie QY, Wang YJ, Sun ZL, Yang TL. Effects of valsartan and indapamide on plasma cytokines in essential hypertension. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2006; 31: 629-634.
39. Zangerle PF, De Groote D, Lopez M, Meuleman RJ, Vrindts Y, Fauchet F, Dehart I, Jadoul M, Radoux D, Franchimont P. Direct stimulation of cytokines (IL-1β, TNF-α, IL-6, IL-2, IFN-γ and GM-CSF) in whole blood: II. Application to rheumatoid arthritis and osteoarthritis. Cytokine. 1992; 4: 568-575.